Systemic Monocyte Chemotactic Protein-1 Inhibition Modifies Renal Macrophages and Restores Glomerular Endothelial Glycocalyx and Barrier Function in Diabetic Nephropathy

American Journal of Pathology

Volumn 187, Issue 11, 2017, Pages 2430-2440

  Boels, Margien G S ^a   Koudijs, Angela ^a   Avramut, M Cristina ^a   Sol, Wendy M P J ^a   Wang, Gangqi ^a   van Oeveren Rietdijk, Annemarie M ^a   van Zonneveld, Anton Jan ^a   de Boer, Hetty C ^a   van der Vlag, Johan ^b   van Kooten, Cees ^a   Eulberg, Dirk ^c   van den Berg, Bernard M ^a   IJpelaar, Daphne H T ^a   Rabelink, Ton J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NOXXON PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CATHEPSIN L; CD206 PROTEIN; CELL PROTEIN; CHEMOKINE RECEPTOR CCR2; CHONDROITIN SULFATE; CREATININE; EMAPTICAP PEGOL; GLUCOSE; HEPARAN SULFATE; HEPARANASE; INSULIN GLARGINE; INTERLEUKIN 10; INTERLEUKIN 6; MAC3 PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEPHRIN; SYNAPTOPODIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CCL2 PROTEIN, MOUSE;

ALBUMIN BLOOD LEVEL; ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; CYTOKINE RELEASE; DIABETIC KETOACIDOSIS; DOWN REGULATION; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME RELEASE; EXPERIMENTAL DIABETIC NEPHROPATHY; FLUORESCENCE ACTIVATED CELL SORTING; GLOMERULAR FILTRATION BARRIER; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS EPITHELIUM; GLUCOSE BLOOD LEVEL; GLYCOCALYX; HEMODYNAMICS; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MOLECULAR PATHOLOGY; MONOCYTE; MOUSE; NONHUMAN; PODOCYTE; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; TISSUE LEVEL; UPREGULATION; ANIMAL; DIABETIC NEPHROPATHY; EXPERIMENTAL DIABETES MELLITUS; KIDNEY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

ANIMALS; CHEMOKINE CCL2; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; GLYCOCALYX; KIDNEY; MACROPHAGES; MALE; MICE, KNOCKOUT; MONOCYTES; PODOCYTES;

EID: 85032696807     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2017.07.020     Document Type: Article

References (40)

1. US Renal Data System Annual Data Report. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Edited by National Institutes of Health. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, 2016. Available at https://www.usrds.org/adr.aspx.
2. Heerspink, H.J., De Zeeuw, D., Novel anti-inflammatory drugs for the treatment of diabetic kidney disease. Diabetologia 59 (2016), 1621–1623.
3. Van Coillie, E., Van Damme, J., Opdenakker, G., The MCP/eotaxin subfamily of CC chemokines. Cytokine Growth Factor Rev 10 (1999), 61–86.
4. Haller, H., Bertram, A., Nadrowitz, F., Menne, J., Monocyte chemoattractant protein-1 and the kidney. Curr Opin Nephrol Hypertens 25 (2016), 42–49.
5. Biswas, S.K., Sodhi, A., Paul, S., Regulation of nitric oxide production by murine peritoneal macrophages treated in vitro with chemokine monocyte chemoattractant protein 1. Nitric Oxide 5 (2001), 566–579.
6. Biswas, S.K., Sodhi, A., In vitro activation of murine peritoneal macrophages by monocyte chemoattractant protein-1: upregulation of CD11b, production of proinflammatory cytokines, and the signal transduction pathway. J Interferon Cytokine Res 22 (2002), 527–538.
7. Tashiro, K., Koyanagi, I., Saitoh, A., Shimizu, A., Shike, T., Ishiguro, C., Koizumi, M., Funabiki, K., Horikoshi, S., Shirato, I., Tomino, Y., Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy. J Clin Lab Anal 16 (2002), 1–4.
8. Nguyen, D., Ping, F., Mu, W., Hill, P., Atkins, R.C., Chadban, S.J., Macrophage accumulation in human progressive diabetic nephropathy. Nephrology 11 (2006), 226–231.
9. Klessens, C.Q., Zandbergen, M., Wolterbeek, R., Bruijn, J.A., Rabelink, T.J., Bajema, I.M., IJpelaar, D.H.T., Macrophages in diabetic nephropathy in patients with type 2 diabetes. Nephrol Dial Transplant 32 (2017), 1322–1329.
10. Chow, F.Y., Nikolic-Paterson, D.J., Ozols, E., Atkins, R.C., Rollin, B.J., Tesch, G.H., Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 69 (2006), 73–80.
11. Ninichuk, V., Clauss, S., Kulkarni, O., Schmid, H., Segerer, S., Radomska, E., Eulberg, D., Buchner, K., Selve, N., Klussmann, S., Anders, H.J., Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-3'PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice. Am J Pathol 172 (2008), 628–637.
12. Darisipudi, M.N., Kulkarni, O.P., Sayyed, S.G., Ryu, M., Migliorini, A., Sagrinati, C., Parente, E., Vater, A., Eulberg, D., Klussmann, S., Romagnani, P., Anders, H.J., Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease. Am J Pathol 179 (2011), 116–124.
13. de Zeeuw, D., Bekker, P., Henkel, E., Hasslacher, C., Gouni-Berthold, I., Mehling, H., Potarca, A., Tesar, V., Heerspink, H.J., Schall, T.J., CCX140-B Diabetic Nephropathy Study Group. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. Lancet Diabetes Endocrinol 3 (2015), 687–696.
14. Menne, J., Eulberg, D., Beyer, D., Baumann, M., Saudek, F., Valkusz, Z., Wiecek, A., Haller, H., Emapticap Study Group. C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria. Nephrol Dial Transplant 32 (2017), 307–315.
15. Boels, M.G., Avramut, M.C., Koudijs, A., Dane, M.J., Lee, D.H., van der Vlag, J., Koster, A.J., van Zonneveld, A.J., van Faassen, E., Grone, H.J., van den Berg, B.M., Rabelink, T.J., Atrasentan reduces albuminuria by restoring the glomerular endothelial glycocalyx barrier in diabetic nephropathy. Diabetes 65 (2016), 2429–2439.
16. Nieuwdorp, M., Mooij, H.L., Kroon, J., Atasever, B., Spaan, J.A., Ince, C., Holleman, F., Diamant, M., Heine, R.J., Hoekstra, J.B., Kastelein, J.J., Stroes, E.S., Vink, H., Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes 55 (2006), 1127–1132.
17. van den Hoven, M.J., Rops, A.L., Bakker, M.A., Aten, J., Rutjes, N., Roestenberg, P., Goldschmeding, R., Zcharia, E., Vlodavsky, I., van der Vlag, J., Berden, J.H., Increased expression of heparanase in overt diabetic nephropathy. Kidney Int 70 (2006), 2100–2108.
18. Garsen, M., Rops, A.L., Dijkman, H., Willemsen, B., van Kuppevelt, T.H., Russel, F.G., Rabelink, T.J., Berden, J.H., Reinheckel, T., van der Vlag, J., Cathepsin L is crucial for the development of early experimental diabetic nephropathy. Kidney Int 90 (2016), 1012–1022.
19. Kalnins, A., Thomas, M.N., Andrassy, M., Muller, S., Wagner, A., Pratschke, S., Rentsch, M., Klussmann, S., Kauke, T., Angele, M.K., Bazhin, A.V., Fischereder, M., Werner, J., Guba, M., Andrassy, J., Spiegelmer inhibition of MCP-1/CCR2: potential as an adjunct immunosuppressive therapy in transplantation. Scand J Immunol 82 (2015), 102–109.
20. Austyn, J.M., Gordon, S., F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur J Immunol 11 (1981), 805–815.
21. Ezekowitz, R.A., Gordon, S., Alterations of surface properties by macrophage activation: expression of receptors for Fc and mannose-terminal glycoproteins and differentiation antigens. Contemp Top Immunobiol 13 (1984), 33–56.
22. Faas, F.G., Avramut, M.C., van den Berg, B.M., Mommaas, A.M., Koster, A.J., Ravelli, R.B., Virtual nanoscopy: generation of ultra-large high resolution electron microscopy maps. J Cell Biol 198 (2012), 457–469.
23. Maecker, H.T., Frey, T., Nomura, L.E., Trotter, J., Selecting fluorochrome conjugates for maximum sensitivity. Cytometry A 62 (2004), 169–173.
24. Ehling, J., Bartneck, M., Wei, X., Gremse, F., Fech, V., Mockel, D., Baeck, C., Hittatiya, K., Eulberg, D., Luedde, T., Kiessling, F., Trautwein, C., Lammers, T., Tacke, F., CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. Gut 63 (2014), 1960–1971.
25. Abboud-Jarrous, G., Atzmon, R., Peretz, T., Palermo, C., Gadea, B.B., Joyce, J.A., Vlodavsky, I., Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J Biol Chem 283 (2008), 18167–18176.
26. Shi, C., Pamer, E.G., Monocyte recruitment during infection and inflammation. Nat Rev Immunol 11 (2011), 762–774.
27. Geissmann, F., Jung, S., Littman, D.R., Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19 (2003), 71–82.
28. Stenvinkel, P., Ketteler, M., Johnson, R.J., Lindholm, B., Pecoits-Filho, R., Riella, M., Heimburger, O., Cederholm, T., Girndt, M., IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia–the good, the bad, and the ugly. Kidney Int 67 (2005), 1216–1233.
29. Goldberg, R., Rubinstein, A.M., Gil, N., Hermano, E., Li, J.P., van der Vlag, J., Atzmon, R., Meirovitz, A., Elkin, M., Role of heparanase-driven inflammatory cascade in pathogenesis of diabetic nephropathy. Diabetes 63 (2014), 4302–4313.
30. Rabelink, T.J., de Zeeuw, D., The glycocalyx: linking albuminuria with renal and cardiovascular disease. Nat Rev Nephrol 11 (2015), 667–676.
31. Zetser, A., Levy-Adam, F., Kaplan, V., Gingis-Velitski, S., Bashenko, Y., Schubert, S., Flugelman, M.Y., Vlodavsky, I., Ilan, N., Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci 117 (2004), 2249–2258.
32. Wang, F., Wang, Y., Zhang, D., Puthanveetil, P., Johnson, J.D., Rodrigues, B., Fatty acid-induced nuclear translocation of heparanase uncouples glucose metabolism in endothelial cells. Arterioscler Thromb Vasc Biol 32 (2012), 406–414.
33. Simeonovic, C.J., Ziolkowski, A.F., Wu, Z., Choong, F.J., Freeman, C., Parish, C.R., Heparanase and autoimmune diabetes. Front Immunol, 4, 2013, 471.
34. Rabelink, T.J., van den Berg, B.M., Garsen, M., Wang, G., Elkin, M., van der Vlag, J., Heparanase: roles in cell survival, extracellular matrix remodelling and the development of kidney disease. Nat Rev Nephrol 13 (2017), 201–212.
35. Bogdani, M., Johnson, P.Y., Potter-Perigo, S., Nagy, N., Day, A.J., Bollyky, P.L., Wight, T.N., Hyaluronan and hyaluronan binding proteins accumulate in both human type 1 diabetic islets and lymphoid tissues and associate with inflammatory cells in insulitis. Diabetes 63 (2014), 2727–2743.
36. Garsen, M., Benner, M., Dijkman, H.B., van Kuppevelt, T.H., Li, J.P., Rabelink, T.J., Vlodavsky, I., Berden, J.H., Rops, A.L., Elkin, M., van der Vlag, J., Heparanase is essential for the development of acute experimental glomerulonephritis. Am J Pathol 186 (2016), 805–815.
37. Creasy, B.M., McCoy, K.L., Cytokines regulate cysteine cathepsins during TLR responses. Cell Immunol 267 (2011), 56–66.
38. Tarabra, E., Giunti, S., Barutta, F., Salvidio, G., Burt, D., Deferrari, G., Gambino, R., Vergola, D., Pinach, S., Perin, P.C., Camussi, G., Gruden, G., Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes. Diabetes 58 (2009), 2109–2118.
39. Faul, C., Donnelly, M., Merscher-Gomez, S., Chang, Y.H., Franz, S., Delfgaauw, J., Chang, J.M., Choi, H.Y., Campbell, K.N., Kim, K., Reiser, J., Mundel, P., The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14 (2008), 931–938.
40. Wada, T., Furuichi, K., Sakai, N., Iwata, Y., Yoshimoto, K., Shimizu, M., Takeda, S.I., Takasawa, K., Yoshimura, M., Kida, H., Kobayashi, K.I., Mukaida, N., Naito, T., Matsushima, K., Yokoyama, H., Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 58 (2000), 1492–1499.